Probiotic Bacillus subtilis B10-based antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: Probiotic Lactobacillus Rhamnosus increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via upregulation of its target gene, 28/February/2019, 8.35 am

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing   Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG)  inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am
February 28, 2019
Probiotics-based immune enhancement therapy: A Probiotic mixture encompassing Lactobacillus plantarum KY1032 and Lactobacillus curvatus HY7601 (LBLC)  increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 28/February/2019, 8.46 am
February 28, 2019
Show all

National Science day special

*********

We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted today (28/February/2019) will be available to the use of Scientists/Professors/Faculties/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today. Each idea posted will be served first come, first serve basis. Write to admin@genomediscovery.org for more details.

Dr L Boominathan PhD

President, Director & CSO, GBMD.

_________________________________________________________________________________________________________________________________________________

 

Introduction: What they say

A study from the Viral Populations and Pathogenesis Unit, Institut Pasteur, CNRS UMR 3569, 25–28 rue du Dr. Roux, 75724 Paris Cedex 15, France shows that “Interferon-Induced Spermidine-Spermine Acetyltransferase and Polyamine Depletion Restrict Zika and Chikungunya Viruses.”  This research paper was published, in the 10 August 2016 issue of the journal “Cell Host and microbe” [One of the best research journals in Infectious biology with an I.F of 12.552], by Prof. Marco Vignuzzi, Bryan C. Mounce and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports, for the first time, that:  Probiotic Bacillus subtilis B10-based antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: Probiotic Lactobacillus Rhamnosus increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via upregulation of its target gene


What is known?

Prof. Marco Vignuzzi’s research team has recently shown that induction of type I interferon results in: a) upregulation of SAT1; b) depletion of spermidine and spermine levels; and c) inhibition of Chikungunya and Zika viruses production. They have further validated this by showing that exogenous administration of Polyamines (spermidine and spermine) restores virus replication.


From research findings to Therapeutic opportunity:

This study suggests, for the first time,  a Probiotic-based antiviral therapy for RNA viruses, such as Chikungunya virus (CHIKV) and Zika virus (ZIKV). Probiotic Bacillus subtilis B10, by increasing the expression of its target gene, it may increase the expression of spermidine/spermine N1-acetyltransferase (SAT1) (Figure 1). Thereby, it may: (1) decrease polyamine spermidine and spermine levels; (2) stall CHIKV and ZIKV replication; (3) promote clearance of Zika and Chikungunya Viruses; and (4) strengthen antiviral immunity against RNA viruses. (Figure 2)

Figure 1 Mechanistic insights into how  Probiotic Lactobacillus Rhamnosus functions as an antiviral agent. Probiotic Lactobacillus rhamnosus inhibits the replication of Chikungunya and Zika viruses through induction of SAT

Figure 2. Probiotic Lactobacillus rhamnosus functions as an anti-CHIKV/ZIKV agent

Thus, pharmacological formulations encompassing Probiotic Bacillus subtilis B10, either alone or in combination with other drugs”, may be used to treat infections caused by chikungunya (CHIKV) and Zika (ZIKV) viruses. Given that probiotic-based therapy is more economical compared with chemical-based anti-viral therapy, Probiotic-based antiviral therapy may find larger utility in patient care throughout the world. 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Probiotic Bacillus subtilis B10 decrease the expression of spermidine/spermine N1-acetyltransferase (SAT1)?

Amount: $1, 500#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L,  Probiotic Bacillus subtilis B10-based antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: Probiotic Lactobacillus Rhamnosus increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via upregulation of its target gene, 28/February/2019, 8.34 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.